高齢患者における急性虚血性脳卒中の治療のための低用量テネクテプラーゼ (DATE-AGING)
高齢患者における急性虚血性脳卒中治療のための低用量テネクテプラーゼの有効性と安全性:前向き、多施設共同、無作為化比較試験
The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Anshan、中国
- Anshan Changda Hospital
-
Anyang、中国
- Anyang People's Hospital
-
Anyang、中国
- Huaxian People's Hospital of Henan
-
Baoshan、中国
- Baoshan People's Hospital
-
Bijie、中国
- People's Hospital of Zhijin County
-
Chongqing、中国
- Chongqing University Three Gorges Hospital
-
Chongqing、中国
- Chongqing University Jiangjin Hospital
-
Chongqing、中国
- Bishan Hospital
-
Chongqing、中国
- Chongqing Emergency Medical Center
-
Chongqing、中国
- Chongqing University Fuling Hospital
-
Chongqing、中国
- Dianjiang People's Hospital OF Chongqing
-
Chongqing、中国
- People's Hospital Of Xiushan County
-
Chongqing、中国
- The People's Hospital of Dazu Chongqing
-
Chongqing、中国
- The People's Hospital of HeChuan, Chongqing
-
Chongqing、中国
- The People's Hospital of Rongchang Chongqing
-
Chongqing、中国
- The People's Hospital of Tongnan District Chongqing City
-
Chongqing、中国
- The Seventh People's Hospital of Chongqing
-
Chongqing、中国
- Tongliang Hospital
-
Chongqing、中国
- Yunyang County People's Hospital
-
Dali、中国
- Dali Bai Autonomous Prefecture People's Hospital
-
Dazhou、中国
- Dazhou Central Hospital
-
Deyang、中国
- The People's Hospital of Zhongjiang
-
Guang’an、中国
- Guang an People's Hospital
-
Guiyang、中国
- Guizhou Provincial People's Hospital
-
Guiyang、中国
- The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
-
Ha’erbin、中国
- The First Affiliated Hospital of Harbin Medical University
-
Hebi、中国
- Xunxian People's Hospital
-
Heyuan、中国
- Heyuan People's Hospital
-
Huanggang、中国
- Qichun People's Hosiptal
-
Jianyang、中国
- The People's Hospital Of Jianyang City
-
Laixi、中国
- Laixi People's Hospital
-
Leshan、中国
- People's Hospital of Leshan
-
Leshan、中国
- Leshan Geriatric Specialized Hospital
-
Luoyang、中国
- Luoyang Mengjin People's Hospital
-
Nanchong、中国
- Nanbu People's Hospital
-
Pujiang、中国
- Puyang People's Hospital
-
Pujiang、中国
- The People's Hospital of Nan Le Xian
-
Shangqiu、中国
- People's Hospital of Ningling County
-
Shangqiu、中国
- The First People's Hospital of Shangqiu
-
Shaoyang、中国
- The First People ' S Hospital of Shao Yang
-
Shijiazhuang、中国
- The People's Hospital of Gaocheng
-
Wuhan、中国
- Wuhan Puren Hospital
-
Xiangyang、中国
- Xiangyang NO.1 People's Hospital
-
Yibin、中国
- The second people's hospital of Yibin
-
Zhumadian、中国
- Zhumadian Central Hospital
-
Zhuzhou、中国
- Zhuzhou Central Hospital
-
Zigong、中国
- Zigong Third People's Hospital
-
Ziyang、中国
- Ziyang Central Hospital
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400038
- Southwest Hospital, Chongqing, China
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150200
- Wuchang People's Hospital
-
-
Henan
-
Zhoukou、Henan、中国、466300
- Shenqiu County People's Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 70 years;
- Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
- Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
- Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
- Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
- Informed consent from the patient or surrogate.
Exclusion Criteria:
-
Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);
-
Acute bleeding diathesis or allergy to tenecteplase, including but not limited to
- Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
- Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
- Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
- Platelet count of below 100×10^9/ L
- Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
- Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
- Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
- Neoplasm with increased haemorrhagic risk
- Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
- History of significant trauma or major surgery within the past 3 months.
- Any known disorder associated with a significant increased risk of bleeding
-
Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
-
Blood glucose <2.8 mmol/L or >22.22 mmol/L;
-
After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;
-
Seizure at stroke onset;
-
Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;
-
Participation in other clinical trials within 3 months prior to screening;
-
Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Low-Dose Tenecteplase
0.175mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient. |
|
アクティブコンパレータ:Standard-Dose Tenecteplase
0.25mg/kg tenecteplase |
Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
時間枠:At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
時間枠:At 24 hours
|
National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits. |
At 24 hours
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
時間枠:At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Distribution of Modified Rankin Scale (mRS)
時間枠:At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
|
Percentage of Participants With Barthel Index Score ≥95
時間枠:up to 90 days
|
The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome. |
up to 90 days
|
|
EQ-5D-5L score
時間枠:At Day 90±7 days
|
Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life) |
At Day 90±7 days
|
|
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
時間枠:up to 36 hours
|
sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline. |
up to 36 hours
|
|
All-cause mortality
時間枠:up to 90 days
|
All-cause mortality at 90 days |
up to 90 days
|
|
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
時間枠:At Day 90±7 days
|
Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). |
At Day 90±7 days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2025IITDA10
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。